Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide not checked
Chiesi Farmaceutici S.p.A. · CHF5993 · HFA-152a propellant
FollowEvery change as it happens, and a Monday email
Trials
5 active
20 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide BDP/FF/GB (100/6/12.5 µg per actuation) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.”In the company’s words, NCT07666490 on ClinicalTrials.gov
- Tested for
- Asthma (3 trials)
- Main trialPhase 4
- “This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.”In the company’s words, NCT07666490 on ClinicalTrials.gov
- Other names
- CHF5993 · TRIMBOW · BDP/FF/GB · HFA-152a propellant · HFA-134a propellant · Beclometasone dipropionate · BecotideTM · CHF5993 + HFA-152a
Other drugs for Asthma
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- 6103SBio · Phase 3
Coming up3
- 3 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 13 Jun 2028Phase 4 trial completes · ClinicalTrials.gov
- 26 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials20
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 13 Jun 2028 | BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) | |
| Phase 3Not yet recruiting | 26 Jun 2030 | Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma | |
| Phase 2Recruiting | 3 Jun 2027 | Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | |
| Phase 4Completed | 24 Feb 2023 | CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD | |
| Phase 3Completed | Jan 2005 | Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma | |
| Phase 3Completed | 10 Jul 2017 | 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients | |
| Phase 3Completed | 17 May 2018 | TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA | |
| Phase 3Completed | 28 May 2018 | TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) | |
| Phase 3Completed | 26 May 2020 | Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI) | |
| Phase 3Completed | 18 Feb 2025 | Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). | |
| Phase 2Completed | 16 Oct 2018 | Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) | |
| Phase 1Completed | Jul 2014 | Drug-drug Interaction Study of CHF5993 With Cimetidine | |
| Phase 1Completed | Apr 2015 | Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers | |
| Phase 1Completed | Jul 2016 | Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers | |
| Phase 1Terminated | 3 Apr 2020 | Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients | |
| Phase 1Completed | 14 Jul 2023 | Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® | |
| Phase 1Completed | 13 Oct 2023 | A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) | |
| Phase 1Ended | not given | A single dose, randomized, double-blind, 2-way crossover clinical pharmacology study, to evaluate the lung availability and the systemic exposure of beclometasone dipropionate and beclometasone 17-monoproprionate (active metabolite of beclometasone dipropionate), after inhalation of CHF 718 pMDI HFA-152a 200 μg 4-inhalations in comparison with CHF 718 pMDI HFA-134a 200 μg 4-inhalations, using Volumatic® spacer in healthy volunteers. | |
| Phase 4Authorised | not given | Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT | |
| Phase 4Authorised | not given | AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026